Orchard Therapeutics plc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash flows from operating activities
Net loss attributable to ordinary shareholders
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
Depreciation and amortization
Share-based compensation
Impairment of long-lived assets
Non-cash interest expense
Amortization of provision on loss contract
Non-cash consideration for licenses and milestones
Deferred income taxes
Amortization of (discount) premium on marketable securities
Unrealized foreign currency gains
Amortization of premium (discount) on marketable securities
Unrealized foreign currency and other non-cash adjustments

Changes in operating assets and liabilities:
Trade and other receivables
Research and development tax credit receivable, prepaids and other assets
Accounts receivable
Research and development tax credit receivable
Prepaid expenses, other current assets, and other assets
Operating leases, right-of-use-assets
Accounts payable
Accrued expenses and other current liabilities
Accounts payable, accrued expenses, and other current liabilities
Deferred revenue
Other long-term liabilities
Operating lease liabilities

Net cash used in operating activities
Cash flows from investing activities
Proceeds from sales and maturities of marketable securities
Purchases of marketable securities
Payment of construction deposit
Receipt of funds from construction deposit
Payments on intangible assets
Purchases of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from modification of credit facility, net of debt issuance costs paid
Issuance of convertible preferred shares, net of issuance costs
Issuance of ADRs in public offerings
Proceeds from share options
Proceeds from employee equity plans
Payment of taxes on restricted stock vesting
Proceeds from issuance of shares as part of collaboration agreement
Proceeds from the issuance of ordinary shares in private placement
Payment of placement agent fees and offering costs
Repayment of notes payable
Net cash (used in) provided by financing activities

Effect of exchange rate changes on cash
Net increase in cash, cash equivalents and restricted cash
Cash, cash equivalents, and restricted cash —beginning of year
Cash, cash equivalents, and restricted cash —end of year
Supplemental disclosure of non-cash investing and financing activities
Intangible assets and property and equipment in accounts payable and accrued expenses
Convertible preferred shares issued for licenses
Shares issued in consideration of license agreements
Employee equity plan proceeds received after year-end

Supplemental disclosure of cash flow information
Lease assets obtained in exchange for new operating lease liabilities
Changes to operating lease right-of-use assets and liabilities from amendments
Cash paid for interest
Cash paid for taxes

Comments